Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off

NCT02764125 is registered in ClinicalTrials.gov with Orion Corporation, Orion Pharma as lead sponsor.

NCT NCT02764125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02764125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off
Lead sponsor
Orion Corporation, Orion Pharma
Phase
Phase 2
Overall status
Completed
Start date
April 8, 2016
Completion date
March 27, 2018
Enrollment
84 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease